QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: CHMP Scientific Opinions and European Commission Marketing Authorisation Decisions

Test your understanding of the concepts covered by CHMP Scientific Opinions and European Commission Marketing Authorisation Decisions.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best distinguishes the CHMP opinion from the European Commission decision in the centralised procedure?

The CHMP adopts the legally operative Union marketing authorisation, while the Commission performs the scientific assessment. The CHMP adopts a formal scientific opinion, while the Commission adopts the legally operative Union decision. The CHMP and Commission jointly sign a single marketing authorisation document. The Commission issues a non-binding scientific recommendation, while the CHMP grants the authorisation.

Question 2 of 10 A regulatory intelligence summary states, "The medicine was approved by EMA in January, and its safety information changed in June." Which revision would provide the best traceability?

The medicine was approved by EMA in January and permanently established in June. CHMP adopted a positive opinion in January; the Commission adopted the marketing authorisation decision later; a subsequent variation modified the authorised product information in June. The Commission adopted a scientific opinion in January, followed by an EMA variation in June. The medicine became authorised when the applicant submitted the dossier, and EMA later edited the leaflet.

Question 3 of 10 Which statement best explains why the CHMP scientific record remains important after the Commission has adopted the authorisation decision?

The CHMP record replaces the legal decision for all regulatory purposes. The CHMP record provides the scientific reasoning and benefit-risk context underlying the authorised conditions. The CHMP record determines current status even after a withdrawal. The CHMP record is needed only to calculate application fees.

Question 4 of 10 What is the significance of a negative CHMP opinion?

It is a scientific conclusion that the committee does not support granting the requested authorisation on the assessed application. It automatically proves that the Commission has adopted a final withdrawal decision. It is legally identical to a Commission refusal in every procedural circumstance. It has no effect because only applicant responses are considered by the Commission.

Question 5 of 10 Which record set would best support inspection readiness for a centrally authorised medicine?

Only the latest package leaflet and launch date Only the CHMP opinion, because it contains the legal authorisation The CHMP opinion, assessment report, Commission decision, annexes, historical product information, subsequent decisions and risk-management records Only internal safety procedures and individual case reports

Question 6 of 10 Which wording is most precise for a formal regulatory report?

EMA approved the product on 10 January. CHMP granted the Union marketing authorisation on 10 January. CHMP adopted a positive opinion on 10 January; the Commission adopted the marketing authorisation decision on 20 February. The European Commission issued an EMA opinion on 10 January.

Question 7 of 10 Why must a regulatory database distinguish an initial negative CHMP opinion from a final opinion following re-examination?

Re-examination can result in a later scientific position, so the initial opinion may not represent the final scientific conclusion. The initial opinion is always deleted once re-examination is requested. Re-examination changes a CHMP opinion into a rapporteur report. The distinction matters only for financial accounting.

Question 8 of 10 A product has a conditional marketing authorisation. What conclusion follows from the article?

A positive CHMP opinion always produces an unrestricted standard authorisation. The product's specific authorisation type and conditions must be identified because they may affect regulatory and pharmacovigilance obligations. Conditional authorisations are scientific opinions rather than legal authorisations. Conditional status removes the need to monitor post-authorisation obligations.

Question 9 of 10 A company database records a product as "EU authorised" on the date of a positive CHMP opinion, although the Commission decision was adopted several weeks later. What is the principal regulatory concern?

The CHMP opinion cannot contain any information about product conditions. The database may incorrectly treat a scientific milestone as the legally operative authorisation event. The Commission decision is relevant only to national marketing authorisations. The CHMP opinion date is always legally irrelevant.

Question 10 of 10 Why should the interval between a CHMP opinion and the Commission decision be retained in regulatory timelines?

It represents a formal transition from scientific assessment to legal decision-making. It proves that the applicant submitted a new marketing authorisation application. It is the period during which the CHMP repeats the entire assessment. It has no regulatory relevance once the CHMP opinion is positive.

Knowledge Assessment: CHMP Scientific Opinions and European Commission Marketing Authorisation Decisions

Cookie Settings